Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03736772 | A Study of LY3090106 in Japanese and Caucasian Healthy Participants | PHASE1 | COMPLETED | 30 | — | — | Nov 19, 2018 | Mar 13, 2019 | May 3, 2019 | 1 | United States |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3090106 | EXPERIMENTAL | LY3090106 administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3090106 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Overtly healthy Japanese or Caucasian * Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²) Exclusion Criteria: * Have participated, within the last 30 days, in a clinical study involving an investigational product (IP). If the previous IP has a long half-li...